Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lisinopril
Drug ID BADD_D01300
Description Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs.[A184853] It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.[A184781,A184808,A184817] ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers.[A184844] Lisinopril was granted FDA approval on 29 December 1987.[L8384]
Indications and Usage Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients ≥6 years, and as an adjunct therapy for heart failure.[L8384,L8387] A combination product with hydrochlorothiazide is indicated for the treatment of hypertension.[L8390]
Marketing Status approved; investigational
ATC Code C09AA03
DrugBank ID DB00722
KEGG ID D00362; D08131
MeSH ID D017706
PubChem ID 5362119
TTD Drug ID D07HGR
NDC Product Code 64220-154; 65862-037; 16571-797; 16571-798; 42708-031; 42708-033; 43353-270; 43353-271; 43547-417; 50090-2228; 50090-4678; 51655-707; 53002-1225; 55154-2128; 60687-325; 60760-359; 61919-246; 62135-641; 63187-099; 63629-8823; 65862-039; 65862-040; 65862-042; 68001-336; 68071-5143; 68084-196; 68645-551; 68645-587; 68645-613; 70518-0117; 70518-2600; 71335-0176; 71335-1380; 71610-612; 0615-8254; 76282-419; 76282-729; 0591-0405; 0591-0409; 0904-6797; 0904-7200; 57297-511; 63827-1012; 16729-376; 16729-379; 43353-113; 43353-993; 43547-351; 43547-355; 50090-3763; 51655-146; 55154-8096; 55289-884; 60687-333; 61919-746; 62135-642; 63187-237; 63187-442; 65862-038; 68001-334; 68071-3220; 68180-982; 68645-608; 68645-610; 68788-6407; 70518-1790; 70518-1906; 0591-0406; 71335-0354; 71610-588; 0615-8253; 72865-208; 72865-209; 76282-422; 76282-731; 76282-733; 82009-063; 65862-041; 65977-0009; 23155-714; 31722-172; 42708-142; 43353-301; 50090-3765; 50090-3774; 50090-4725; 50090-4885; 50436-0352; 50436-0354; 51655-399; 51655-729; 51655-999; 58118-1980; 60687-678; 60760-380; 62135-644; 63187-775; 63629-5247; 67296-1202; 67296-1839; 68180-517; 68180-981; 68645-550; 68645-555; 69117-0037; 70882-104; 71205-471; 71335-1295; 71610-624; 0615-8255; 61919-909; 62135-645; 63187-257; 63187-821; 63629-8736; 68001-335; 68180-513; 68645-593; 68788-7012; 68788-7334; 69117-0036; 70518-0544; 70882-103; 70934-155; 71205-180; 71205-742; 71335-0015; 71610-638; 0615-8405; 72865-210; 82009-065; 82982-066; 14593-944; 17404-0011; 16571-794; 16571-795; 42708-154; 43547-418; 43547-419; 50090-0808; 52427-441; 58118-1981; 60760-360; 61919-721; 62135-643; 63187-534; 63629-1761; 67296-1452; 68001-337; 68071-3123; 68645-552; 68645-553; 68645-609; 68788-6820; 68788-6920; 69117-0038; 69117-1003; 70518-1152; 70882-110; 70934-338; 70934-522; 70934-919; 71205-071; 76282-728; 76282-730; 82009-066; 0591-0885; 16571-796; 16729-377; 43063-480; 43063-810; 43063-812; 43547-353; 51655-486; 52427-438; 53002-1123; 60687-646; 60687-667; 63187-825; 68001-332; 68001-486; 68071-3409; 68071-5190; 68180-512; 68180-979; 68180-980; 68645-554; 68645-611; 68788-8351; 70518-0468; 70934-171; 71205-626; 0615-8252; 0904-6800; 67651-0225; 31722-179; 31722-180; 42708-176; 43063-769; 43547-352; 43547-354; 43547-356; 50090-2989; 50090-3175; 51655-995; 52652-3001; 53002-1178; 53002-1463; 60760-358; 60760-390; 60760-438; 61919-717; 61919-736; 63187-098; 63187-780; 68001-333; 68071-2224; 68071-3411; 68084-765; 70518-2561; 70518-2655; 0591-0407; 72789-093; 72789-101; 72865-211; 76282-420; 76282-421; 82009-064; 64220-142; 16729-380; 23155-710; 23155-711; 23155-712; 43063-786; 43063-800; 43063-811; 43063-813; 43353-297; 43353-643; 43353-662; 43353-793; 43547-415; 50090-6303; 51655-335; 51655-411; 52427-442; 62135-640; 63187-722; 68071-3064; 68788-8310; 69117-1001; 71335-0075; 71610-312; 71610-406; 71610-536; 72865-212; 76282-418; 0904-6798; 0904-6799; 65730-1301; 42708-096; 42708-165; 50090-2431; 50090-4887; 52427-443; 55154-4992; 55154-8078; 55700-480; 60760-357; 60760-455; 68645-532; 70518-1156; 70518-1316; 70518-3166; 0591-0408; 76282-417; 16571-799; 16729-375; 31722-176; 31722-178; 42708-032; 43063-074; 43353-009; 43353-298; 43547-414; 43547-416; 50090-5120; 50436-0353; 51655-994; 52427-440; 53002-2123; 55154-2329; 55700-479; 55700-547; 60687-656; 67296-1154; 68645-612; 68788-7666; 69117-1002; 71335-0498; 71335-0536; 72865-213; 76282-732; 82009-062; 16729-378; 23155-713; 23155-715; 31722-177; 42708-094; 43063-814; 43063-815; 52427-439
UNII E7199S1YWR
Synonyms Lisinopril | Lysinopril | Lisinopril Sulfate (1:2) | Prinivil | Zestril | Lisinopril Maleate (1:1) | MK-521
Chemical Information
Molecular Formula C21H31N3O5
CAS Registry Number 76547-98-3
SMILES C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tubulointerstitial nephritis20.05.02.0020.000019%Not Available
Seasonal allergy22.04.04.008; 10.01.04.001; 06.04.01.0130.000007%Not Available
Red blood cell sedimentation rate increased13.01.03.001--Not Available
Food aversion19.09.03.002; 14.03.02.0290.000005%Not Available
Anal haemorrhage07.12.03.004; 24.07.02.0290.000005%
Left ventricular dysfunction02.04.02.0110.000005%
Muscle tightness15.05.03.0070.000009%Not Available
Skin tightness23.03.03.0180.000010%Not Available
Lacunar infarction24.04.06.009; 17.08.01.0160.000007%Not Available
Blood pressure inadequately controlled24.06.01.0070.000064%Not Available
Systemic inflammatory response syndrome24.06.03.008; 10.02.01.008; 08.01.05.0050.000005%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.000014%Not Available
Circumoral oedema23.04.01.012; 10.01.05.0130.000021%Not Available
Lymphatic disorder01.09.01.003--Not Available
Oral pruritus07.05.05.0020.000009%Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.0010.000007%Not Available
Alcohol withdrawal syndrome19.07.06.005; 08.06.02.0020.000007%Not Available
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.0010.000025%Not Available
Application site swelling08.02.01.027; 12.07.01.0270.000010%Not Available
Secretion discharge08.01.03.0190.000012%Not Available
Tonsillar disorder22.04.05.0090.000005%Not Available
Type IV hypersensitivity reaction10.01.03.0220.000012%Not Available
Growth retardation05.03.02.007; 15.03.05.016; 14.03.02.0310.000005%
Depressive symptom19.15.02.003--Not Available
Fluid intake reduced14.05.10.0010.000015%Not Available
Faecaloma07.01.03.0040.000005%Not Available
Colitis microscopic07.08.01.0110.000014%Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.000026%Not Available
Paraesthesia oral17.02.06.008; 07.05.05.0350.000021%Not Available
The 13th Page    First    Pre   13 14 15 16 17    Next   Last    Total 17 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene